EUVIMEDEUVIMED entdecken
Crossref

Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France

L Sagaon-Teyssier iD, A Eremin iD, M A Valantin, A Fauchois, R Tubiana, S Seang, L Schneider, A Fayçal, S Saliba, M Wirden iD, C Soulié iD, G Peytavin iD und 4 weitere

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von L Sagaon-Teyssier und 15 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille Univ, IRD, Inserm, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, Fran…. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Antiretroviral Therapy, Highly Active. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Recherche et d'Études sur la Pathologie Tropicale et le Sida (CREPATS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While current HIV care includes drug-reduced antiretroviral strategies, intermittent therapy, recently recommended in France, could benefit from further evaluation in real-life clinical practice.

Objectives

To evaluate the uptake, efficacy and cost impact of drug-reduced antiretroviral strategies (DRS) in a large HIV clinic in Paris.

Methods

This retrospective study included all virally suppressed adult individuals living with HIV treated at our clinic from 2015 to 2022, on three-drug (3-DR) or two-drug (2-DR) daily regimens, with ≥1 clinical and viral load assessment recorded per year. We defined DRS as either 2-DR or intermittent oral regimen (4 or 5 days weekly). Main outcomes included DRS uptake, factors associated with DRS prescription, virological failure (VF) by ART strategy and costs.

Findings

We analysed 2170 individuals (median age: 50.6, viral suppression: 6.0 years) on daily 3-DR (77.5%) and 2-DR (22.5%). Over 8 years, 1048 participants (48.3%) switched to a DRS that consisted of intermittent ART (ART-I) in 580 participants and a 2-DR in 442 participants. The VF rate was 11.2% for 3-DR, 5.3% for 2-DR and 1.8% for intermittent ART. Overall, in 2022, 1184 participants (54.6%) were receiving a DRS. Average yearly cost of HIV care per participant dropped from €15 687 in 2015 to €7437 in 2022, with per-participant costs of €7643 for 3-DR, €8869 for 2-DR and €3388 for ART-I.

Conclusions

Drug-reduced ART regimens were prescribed to over half of the study population. Intermittent regimens, widely used in our setting, are highly effective and cost-saving, and deserve to be evaluated for implementation, particularly in resource-constrained contexts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveHumansRetrospective StudiesMaleFemaleMiddle AgedParisAdultViral Load

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Aix Marseille Univ, IRD, Inserm, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France.
  • Infectious Diseases Department, Sorbonne University, Pitié-Salpêtrière Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (IPLESP), INSERM 1136, Paris, France.
  • Virology Department, Sorbonne University, Pitié-Salpêtrière Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (IPLESP), INSERM 1136, Paris, France.
  • Pharmacology Department, Bichat Claude-Bernard University Hospital, AP-HP, Paris, France.

ORCID-Profile: L Sagaon-Teyssier, A Eremin, M Wirden, C Soulié, G Peytavin, V Pourcher, R Palich

Förderung

  • Recherche et d'Études sur la Pathologie Tropicale et le Sida (CREPATS)

Zitieren

APA

Sagaon-Teyssier, L., Eremin, A., Valantin, M. A., Fauchois, A., Tubiana, R., Seang, S., Schneider, L., Fayçal, A., Saliba, S., Wirden, M., Soulié, C., Peytavin, G., Pourcher, V., Agher, R., Palich, R., & Katlama, C. (2025). Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf307

Vancouver

Sagaon-Teyssier L, Eremin A, Valantin MA, Fauchois A, Tubiana R, Seang S, et al. Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf307

BibTeX
@article{SagaonTeyssier2025,
  author = {Sagaon-Teyssier, L and Eremin, A and Valantin, M A and Fauchois, A and Tubiana, R and Seang, S and Schneider, L and Fayçal, A and Saliba, S and Wirden, M and Soulié, C and Peytavin, G and Pourcher, V and Agher, R and Palich, R and Katlama, C},
  title = {Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf307}
}
Kostenlos starten →